Paediatric patients who have undergone an organ transplant face risks associated with different infec tious diseases. Their susceptibility is increased by treatment with immunosuppressive medications. More of these patients are being cared for in com munity settings. This practice point provides guid ance on key aspects in the prevention and treat ment common infections.
The paediatric patient undergoing an organ transplant is at risk of acquiring various infectious diseases from three possible sources: the endogenous reactivation of latent pathogens (eg, herpes viruses); transmission from the donated organ or tissue; or transmission from within the community or health care setting. Clinicians practicing in community settings often provide care for these vulnerable patients before or after transplanta tion. Guidelines for the prevention and treatment of these infections were recently published [1] and reviews have been written. [2] This practice point summarizes key aspects of managing transplant patients, with a fo cus on issues likely to be encountered in community settings.
Preparing the patient
The pretransplant period should be used to improve a patient's overall health and well-being as much as pos sible, with particular emphasis on optimizing vaccina tion status (Table 1) . The likelihood of an adequate im mune response improves when vaccines are adminis tered before the onset of immune suppression. As a general rule, the interval between administering an in activated vaccine and transplantation should be more than two weeks to allow for an adequate immune re sponse. [3] - [4] The minimum interval between the last dose of a 'live' vaccine and onset of immune suppres sion should be four weeks. [3] - [4] Live vaccines (eg, measles vaccine) are relatively contraindicated after transplantation. Also, the patient's household contacts should have received all age-appropriate vaccines for measles, mumps, rubella, varicella, pertussis, Haemophilus influenzae type b, meningococcal, pneu mococcal, rotavirus, and the seasonal influenza vac cine. A second focus in the pretransplant period should be on identifying acute, chronic or latent infections in the transplant candidate as well as in prospective living donors. While this practice point concentrates primarily on the transplant candidate or recipient, clinicians will also need to work closely with their transplant centre and be familiar with protocols for living donor screen ing. Specific conditions may be determined by patient history (including risks associated with tuberculosis ex posure, travel, living abroad, household pets, lifestyle and occupation), by the physical examination or by screening tests (Table 2) . Pre-existing infections can contraindicate or delay transplantation. Detailed pa tient information is critical for assessing the risk of post-transplant infection and for guiding post-trans plant prophylaxis (Table 3) . Counselling on how to avoid high-risk exposures in the immediate pretrans plant period (eg, around lifestyle, travel, food and wa ter sources) should be provided to both recipient and donor.
Post-transplant infections to expect
In the first month Greater than 95% of infections occurring in this critical period are similar to infections incurred by nonimmuno suppressed patients who have undergone a compara ble surgical procedure. [5] - [6] The remaining are caused either by an infection that was present in the recipient before transplantation that was exacerbated by surgery, anesthesia and immunosuppressive therapy, or by an infection being transmitted by the allograft.
One to six months post-transplant
In this period, the effects of immune suppression be come noticeable and may result in two types of oppor tunistic infections. In the first category are viral pathogens that are associated with latent or persistent infections, including cytomegalovirus (CMV), EpsteinBarr virus (EBV), human herpes virus 6, and hepatitis B and C viruses. Infection by these pathogens can be primary (typically acquired from the donor rather than from the community), a reactivation of latent pathogens, or reinfection with a new strain of the virus. Typical pathogens in the second category are Listeria monocytogenes, Aspergillus fumigatus and Pneumo cystis jirovecii. Infection development with these or ganisms is aided by sustained immunosuppression with or without the immunomodulating effects of viral infections to create a net state of immunosuppression sufficient to increase susceptibility. Some organ trans plants (eg, of the small bowel) carry higher risks of op portunistic infection compared with others (eg, the kid ney) because immunosuppression is more intense.
More than six months post-transplant
Published data on infectious complications in this peri od are limited and may be biased toward serious infec tions that require hospitalization. Patients who are on maintenance immunosuppression and have good allo graft function are likely to acquire the same communi ty-acquired infections as healthy children (eg, common respiratory viruses). Some patients with poorer posttransplant outcomes (eg, acute or chronic immunosup pression, poor allograft function or a chronic viral infec tion) are at high risk for recurrent infections relating to uncorrected mechanical or anatomical problems (eg, implanted foreign material or an obstruction), as well as for opportunistic infections from P jirovecii, L mono cytogenes, Cryptococcus neoformans, and Nocardia asteroides, among others.
Evaluation of the febrile transplant patient
Fever in the transplant patient may be due to a com mon childhood infection or to an infection that is unique to the transplant recipient. [2] The timing of infec tion after transplantation provides guidance regarding the most likely pathogens. Evaluation and empirical therapy will depend on the clinical status of the patient and whether or not a source of infection has been identified.
When the examination is abnormal and the focus of infection is defined
Hospital admission may be indicated, depending on the clinical status of the patient and the site of infec tion. Diagnostic evaluation should include, at a mini mum, a complete blood count and differential, and blood cultures. Additional investigations depend on the clinical focus and timing of presentation after trans plantation.
When the examination is normal and no focus of infection is defined
Hospital admission is usually warranted if the patient is clinically unwell. Diagnostic evaluation is based on the differential diagnoses. Patients who feel well may not require admission, depending on the adequacy of available follow-up, their ability to return to the hospital promptly if a condition worsens, the degree of immune suppression and the interval since transplantation. Di agnostic evaluation should include, at a minimum, a complete blood count and differential, and blood and urine cultures. In the first months following a trans plant, the site of infection often relates to the surgical procedures performed. Clinicians need to be aware of viral infections that are associated with fever but have no readily apparent focus of infection (eg, CMV and adenovirus). In the absence of an obvious benign source of fever, such patients should be managed in consultation with their transplant centre. When choos ing antibiotics for infections (as appropriate), clinicians need to be aware of potential interactions between an tibiotics and selected immunosuppressive drugs; Table  4 lists immunosuppressive agents, while Table 5 shows potential drug interactions.
Post-transplant immunizations
Timing and schedule Most transplant centres provide schedules for immu nizing recently transplanted paediatric patients (Table  1) . Usually, vaccines are not administered in the first six to 12 months following a transplant [7] with the ex ception of the seasonal inactivated influenza vaccine, which is administered no earlier than one month after transplantation and yearly thereafter. Clinicians should acquaint themselves with appropriate vaccination schedules. Also, vaccinating household contacts is a key strategy in protecting the vulnerable transplant re cipient.
Contraindicated vaccines
Vaccines that are contraindicated for immunosup pressed transplant patients are shown in Table 3 . Some groups recommend giving measles, mumps and rubella vaccines in select low-risk patients with minimal immunosuppression. [3] [8]- [9] Limited data exist for ad ministering the varicella vaccine after transplantation. [10] - [11] However, most experts consider organ trans plant to be a contraindication for the varicella vaccine and, in the event of exposure, susceptible individuals are candidates for varicella-zoster immune globulin. This issue underscores the importance of pretrans plant vaccination. Vaccinating paediatric transplant candidates has been shown to sustain humoral immu nity for at least two years, well beyond the period of peak immunosuppression. [12] Selected indicated vaccines Pneumococcal vaccines: Transplant patients are considered to be at high-risk of invasive pneumococcal disease, with heart transplant recipients being particu larly vulnerable. [13] - [14] Consequently, pneumococcal vaccine is one of the most important vaccines given to transplant recipients. Current recommendations are for sequential use of the 13-valent pneumococcal conju gate vaccine (with the number of doses depending on the age of the child) followed in eight weeks by the 23-valent vaccine. [15] - [16] Some organ transplant patients with functional or anatomical asplenia are candidates for long-term penicillin prophylaxis to prevent invasive pneumococcal disease.
Meningococcal vaccines: These vaccines may be safely administered using routine childhood schedules. The meningococcal conjugate quadrivalent vaccine (MCV), rather than the polysaccharide quadrivalent vaccine, should be used. Most experts agree there is no role for the polysaccharide vaccine at present. The meningococcal conjugate quadrivalent vaccine is not approved for children younger than 24 months of age.
Human papilloma virus vaccine:
The human papillo ma virus (HPV) vaccine can be safely administered af ter an organ transplant. While data are lacking to sup port the efficacy of HPV vaccine in recipients whose immune responses may be weaker than those of healthy individuals, the vaccine is strongly recom mended for both female and male transplant patients given their particular risk of developing severe genital warts and potentially aggressive HPV-related malig nancies.
Hepatitis B and A vaccines:
Hepatitis B vaccine should be given according to the routine immunization schedule, but with double the usual dose. Hepatitis A vaccine is usually recommended for individuals with risk factors for hepatic disease other than transplanta tion (eg, chronic liver disease or epidemiological fac tors). However, some experts recommend hepatitis A vaccine even if other risk factors are absent because potentially hepatotoxic drugs may be used to treat im munosuppression. Inactivated polio, Haemophilus influenzae type b and diphtheria, tetanus and acellular pertussis vaccines: These vaccines are all recommended, preferably before transplantation, in accordance with the routine schedule for children. If not previously re ceived, Haemophilus influenzae type b vaccine should be given, regardless of age.
Influenza vaccine:
Transplant recipients and all household and other close contacts should receive in activated influenza vaccine yearly during the fall.
Community-acquired respiratory viruses
Paediatric organ transplant recipients are at risk for community-acquired respiratory viral infections, includ ing respiratory syncytial virus, influenza viruses, hu man metapneumovirus, parainfluenza viruses and oth ers. [17] Guidelines for preventing and managing these infections were published recently, [18] - [19] and influenza management guidelines are published annually in Canada. [20] 
Post-transplant targets for antimicrobial prohylaxis
Transplant patients may require antimicrobial prophy laxis against Candida species, Aspergillus species, herpes group viruses (eg, herpes simplex, CMV, EBV), hepatitis B, P jirovecii, Toxoplasma gondii, Strongy loides, latent tuberculosis infection and other pathogens ( Table 2) . Of these infective agents, CMV and EBV consume the greatest resources in most pae diatric transplant centres. Guidelines on the prevention and treatment of these conditions have been recently updated. [1] [21]- [22] 
Infection risks of daily living after a transplant
Besides providing information on the risks of immuno suppressive drugs (Table 4) [23] and their interactions with common antimicrobials (Table 5) , clinicians need to counsel young transplant patients about infection risks associated with food and drinking water, pets and other animals, swimming and other water sports, fun gal spores (eg, from gardening, farm buildings, con struction sites, excavations, caves, marijuana and to bacco), mosquito bites, travel and sexual behaviour, as appropriate. [19] Respiratory tract pathogens Obtain sputum cultures from patients with cystic fibrosis and other lung transplant candidates; pretransplant antimicrobial susceptibility data for colonizing bacteria (eg, Burkholderia cepacia) will guide peritransplant an timicrobial therapy; Aspergillus colonization is an indication for suppressive therapy.
Radiographic imaging Obtain as clinically indicated
Adapted from reference 2. *Maternal antibody may lead to false positive serological tests among infants <18 months of age, and false positive tests due to passively transfused antibody may be obtained after recent receipt of blood products; † A negative polymerase chain reaction (PCR) does not rule out latent infection in the in fant. This is not an all-inclusive list. Other screening tests may be indicated for specific pathogens (eg, syphilis, and Kaposi's sarcoma-associated herpesvirus [HHV8] for individuals from endemic areas. Generally, HHV8 seroprevalence rates are as follows: North America, Asia, northern Europe <5%; Mediterranean basin, Caribbean, Middle East 5% to 20%; Africa, Amazon basin >50%.(24) HTLV Human T-lymphotrophic virus; IgG Immunoglobulin G; IGRA Interferon gamma release assays; TB Tuberculosis 
Antivirals
Nevirapine Efavirenz Indinavir Nelfinavir Ritonavir Lopinavir Amprenavir Saquinavir *Degree of inhibition/induction of CYP p450 enzymes is drug-and/or route-specific, affecting the degree of interaction with listed immunosuppressants. The above drug interactions do not preclude use of these antimicrobial agents. However, strategies to manage and monitor interactions/drug levels should be discussed with the transplant team before initiation. AUC Area under the curve; CYP Cytochrome p450
